- ISIN
- US29089Q1058
- CUSIP
- 29089Q105
- Sector
- Healthcare
- IPO Date
- Nov 15, 2006
Highlights
- Market Cap
- $372.53M
- Enterprise Value
- $785.83M
- EPS (TTM)
- -$0.41
- Total Revenue (TTM)
- $676.80M
- Gross Profit (TTM)
- $292.40M
- EBITDA (TTM)
- $126.60M
- Year Range
- $5.62 - $14.06
- Target Price
- $12.00
- ROA (TTM)
- -1.17%
- ROE (TTM)
- -2.94%
- Avg. Volume (1M)
- 672K
- Avg. Volume Value (1M)
- $5.21M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
EBS Performance Chart
Emergent BioSolutions Inc. (EBS) is down 41.6% since the beginning of the year. At $7 per share, EBS is trading 48.6% below its 52-week high of $14. Investors who bought $1,000 worth of EBS shares 5 years ago would now be looking at an investment worth $110.
Loading charts...
Compare this symbol against anything
Returns By Period
Emergent BioSolutions Inc. (EBS) has returned -41.59% so far this year and 28.24% over the past 12 months. Over the last ten years, EBS has returned -13.41% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.
Emergent BioSolutions Inc.
- 1D
- -0.55%
- 1M
- -12.80%
- 6M
- -36.33%
- YTD
- -41.59%
- 1Y
- 28.24%
- 3Y*
- -3.00%
- 5Y*
- -35.74%
- 10Y*
- -13.41%
- ALL TIME*
- -2.46%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
EBS Monthly Returns History
Based on dividend-adjusted daily data since Nov 15, 2006, EBS's average daily return is +0.07%, while the average monthly return is +1.59%. At this rate, an investment would double in approximately 3.7 years.
Historically, 53% of months were positive and 47% were negative. The best month was May 2024 with a return of +203.2%, while the worst month was Nov 2007 at -44.5%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 9 months.
On a daily basis, EBS closed higher 49% of trading days. The best single day was Feb 21, 2024 with a return of +78.3%, while the worst single day was Aug 7, 2024 at -42.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.25% | -28.13% | 1.84% | -0.84% | 10.81% | -8.11% | -13.84% | -41.59% | |||||
| 2025 | 17.68% | -33.51% | -35.03% | 9.88% | 18.35% | 0.95% | -7.84% | 41.16% | 6.27% | 41.50% | -10.50% | 10.65% | 29.29% |
| 2024 | -30.42% | 93.41% | -21.67% | -25.69% | 203.19% | 19.65% | 86.36% | -34.62% | 0.48% | 8.50% | 11.70% | -5.53% | 298.33% |
| 2023 | 11.69% | -6.14% | -16.32% | -14.77% | -3.40% | -13.83% | -6.39% | -31.83% | -27.51% | -38.53% | 2.39% | 12.15% | -79.68% |
| 2022 | 7.66% | -11.58% | -0.77% | -21.14% | 1.79% | -5.83% | 11.60% | -30.66% | -12.61% | -0.62% | -41.04% | -3.98% | -72.83% |
| 2021 | 19.25% | -10.15% | -3.22% | -34.37% | -0.54% | 3.86% | 4.62% | -4.28% | -20.62% | -4.79% | -7.45% | -1.47% | -51.48% |
Benchmark Metrics
Emergent BioSolutions Inc. has an annualized alpha of 8.27%, beta of 1.04, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since November 15, 2006.
- This stock participated in 145.68% of S&P 500 Index downside but only 101.70% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 8.27%
- Beta
- 1.04
- R²
- 0.09
- Upside Capture
- 101.70%
- Downside Capture
- 145.68%
Return for Risk
Risk / Return Rank
EBS ranks 58 for risk / return — above 58% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Emergent BioSolutions Inc. (EBS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| EBS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.13 | ||
| Sortino ratioReturn per unit of downside risk | -0.88 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.25 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 0.48 | 2.00 | -1.53 |
| Martin ratioReturn relative to average drawdown | 0.80 | 8.49 | -7.69 |
Dividends
Dividend History
Emergent BioSolutions Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.86 |
Dividend yield | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.65% |
Monthly Dividends
The table displays the monthly dividend distributions for Emergent BioSolutions Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Emergent BioSolutions Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Emergent BioSolutions Inc. was 98.89%, occurring on Feb 7, 2024. The portfolio has not yet recovered.
The current Emergent BioSolutions Inc. drawdown is 94.65%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-98.89%Feb 2024 | 3y 5mo | — | 5y 11moAug 2020 - now | — |
-72.26%Dec 2007 | 10mo 29d | 10mo 5d | 1y 8moJan 2007 - Oct 2008 | Financial crisis2007–2009 |
-63.37%May 2009 | 4mo 1d | 4y 8mo | 5y 17dJan 2009 - Jan 2014 | Financial crisis2007–2009 |
-45.49%May 2019 | 5mo 28d | 10mo 29d | 1y 4moDec 2018 - Apr 2020 | — |
-41.10%Nov 2016 | 4mo 29d | 1y | 1y 4moJun 2016 - Nov 2017 | — |
Drawdown Indicators
| EBS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.89% | -56.78% | -42.11% |
Max Drawdown (1Y)Largest decline over 1 year | -48.06% | -9.10% | -38.96% |
Max Drawdown (3Y)Largest decline over 3 years | -79.73% | -18.90% | -60.83% |
Max Drawdown (5Y)Largest decline over 5 years | -97.67% | -25.43% | -72.24% |
Max Drawdown (10Y)Largest decline over 10 years | -98.89% | -33.92% | -64.97% |
Current DrawdownCurrent decline from peak | -94.65% | -1.58% | -93.07% |
Average DrawdownAverage peak-to-trough decline | -41.53% | -10.70% | -30.83% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 28.48% | 2.14% | +26.34% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Emergent BioSolutions Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Emergent BioSolutions Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for EBS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, EBS has a P/S ratio of 0.4. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with EBS
Add Emergent BioSolutions Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with EBS